[Localized scleroderma: a retrospective study about 92 cases].
BACKGROUND
Sclerodermas are rare affections which can be located or generalized. Localized form is the most frequent.


OBJECTIVE
The purpose of this study was to describe epidemiologic, clinics, biological, immunological, therapeutic, evolutionary characteristics of the localized scleroderma through a personal series and the data of the literature.


METHODS
We have performed a retrospective study on all patients followed in the department of dermatology of the Hospital Charles Nicole during 14 years period.


RESULTS
Our study was about 92 cases of localized scleroderma (73 were females and 19 males). The mean age was 35 years (between 2 and 72 years). The majority of localised sclerodermas (66.2% of the cases) appeared before 40 years with a maximum of frequency between 10 and 30 years (41.6%). Only 11.9% of the cases were observed before 10 years. They were 51 cases (55%) of morphea, 35 cases (38%) of scleroderma in bands including 32 linear scleroderma and 3 scleroderma en coup de sabre, 5 cases (5.5%) of generalized morphea and 1 case (0.15%) of deep morphea. Average therapeutic was specified among 63 patients (87%), and the evolution could be appreciated among 45 patients.


CONCLUSIONS
The epidemiologic data observed in our series are comparable with those reported in the literature. Therapeutic difficulties and risks of functional after-effects, particular in scleroderma in bands, remain the principal concern for all the authors.
El Fékih
Nadia
N
Service de dermatologie Hôpital Charles Nicolle Tunis Tunisie.
Réjaibi
Iménc
I
Kamoun
Hajer
H
Zéglaoui
Faten
F
Fazaa
Bécima
B
Kharfi
Monia
M
Kamoun
Mohamed Ridha
MR
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012594:Scleroderma, Localized / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011241:Prednisone